KR960037682A - 축합 6환 화합물 및 그의 제조방법 - Google Patents

축합 6환 화합물 및 그의 제조방법 Download PDF

Info

Publication number
KR960037682A
KR960037682A KR1019960010291A KR19960010291A KR960037682A KR 960037682 A KR960037682 A KR 960037682A KR 1019960010291 A KR1019960010291 A KR 1019960010291A KR 19960010291 A KR19960010291 A KR 19960010291A KR 960037682 A KR960037682 A KR 960037682A
Authority
KR
South Korea
Prior art keywords
methanesulfonic acid
rti
protecting group
compound
methanesulfonate
Prior art date
Application number
KR1019960010291A
Other languages
English (en)
Other versions
KR100400941B1 (ko
Inventor
신지 가미하라
카주아키 가나이
시게루 노구치
히로푸미 데라사와
히로아키 기타오카
Original Assignee
스즈키 다다시
다이이치 세야쿠 가부시키가이샤
구와하라 준
가부시키가이샤 야쿠루토 혼샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스즈키 다다시, 다이이치 세야쿠 가부시키가이샤, 구와하라 준, 가부시키가이샤 야쿠루토 혼샤 filed Critical 스즈키 다다시
Publication of KR960037682A publication Critical patent/KR960037682A/ko
Application granted granted Critical
Publication of KR100400941B1 publication Critical patent/KR100400941B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

본 발명은 식(2)로 표시되는 화합물을 메탄술폰산으로 처리한 후, 재결정하여 식(1)로 표시되는 화합물의 제조방법 및 이렇게 얻어진 화합물(1)을 개시한다.
본 화합물(1)은 흡습하지 않고, 여과성 및 용해성이 우수하고, 취급이 용이하다. 더욱이 본 발명의 제조방법에 따라 불필요한 이성체를 목적 이성체로 변환시킬 수 있고, 재결정함으로써 목적물을 쉽게 분리할 수 있다.

Description

축합 6환 화합물 및 그의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 본 발명과 비교품의 흡수에 의한 중량변화를 나타내는 도면이다.

Claims (7)

  1. 다음 식(1)
    로 표시되는 캄프토테신 유도체의 메탄술폰산염 또는 그의 수화물.
  2. 다음 식(1)
    로 표시되는 캄프토테신 유도체의 메탄술폰산염 또는 그의 수화물과 약학적으로 허용되는 염을 함유하는 의약 조성물.
  3. 제2항에 있어서, 항종양 의약 조성물인 조성물.
  4. 다음 식(2)
    (식중, X는 메탄술폰산에 의해 제거될 수 있는 보호기를 나타낸다.)로 표시되는 화합물을 메탄술폰산으로 처리한 후, 재결정함을 특징으로 하는 다음 식(1)
    로 표시되는 캄프토테신 유도체의 메탄술폰산염의 제조방법.
  5. 다음 식(3)
    (식중, X는 메탄술폰산에 의해 제거될 수 있는 보호기를 나타낸다.)로 표시되는 화합물의 아미노기를 메탄술폰산에 의해 제거될 수 있는 보호기로 보호하고, 메탄술폰산으로 처리한 후, 재결정함을 특징으로 하는 다음 식(1)
    로 표시되는 캄프토테신 유도체의 메탄술폰산염의 제조방법.
  6. 제4항 또는 제5항에 있어서, 메탄술폰산에 의해 제거될 수 있는 보호기가 아세틸기인 것이 특징인 방법.
  7. 제4항, 제5항 또는 제16항에 있어서, 재결정에 사용되는 용매가 물과 알코올의 혼합 용매인 것이 특징인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960010291A 1995-04-10 1996-04-04 축합6환화합물및그의제조방법 KR100400941B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP83717/1995 1995-04-10
JP8371795 1995-04-10

Publications (2)

Publication Number Publication Date
KR960037682A true KR960037682A (ko) 1996-11-19
KR100400941B1 KR100400941B1 (ko) 2003-12-24

Family

ID=13810270

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960010291A KR100400941B1 (ko) 1995-04-10 1996-04-04 축합6환화합물및그의제조방법

Country Status (13)

Country Link
US (2) US6504029B1 (ko)
EP (1) EP0737686B1 (ko)
KR (1) KR100400941B1 (ko)
CN (1) CN1050131C (ko)
AT (1) ATE181919T1 (ko)
CA (1) CA2173671A1 (ko)
DE (1) DE69603117T2 (ko)
DK (1) DK0737686T3 (ko)
EA (1) EA000036B1 (ko)
ES (1) ES2136338T3 (ko)
GR (1) GR3031400T3 (ko)
NO (1) NO314085B1 (ko)
TW (1) TW382630B (ko)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2273841T3 (es) 2000-02-28 2007-05-16 Pfizer Enterprises Sarl Combinacion sinergica para el tratamiento de cancer colorrectal.
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
US6548488B2 (en) 2000-03-17 2003-04-15 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
AR030207A1 (es) * 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
PL365685A1 (en) 2000-10-27 2005-01-10 Aventis Pharma S.A. A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
WO2006069344A2 (en) 2004-12-22 2006-06-29 Rutgers, The State University Of New Jersey Controlled release hydrogels
US8410045B2 (en) 2006-03-30 2013-04-02 Drais Pharmaceuticals, Inc. Camptothecin-peptide conjugates and pharmaceutical compositions containing the same
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
AU2009329867B2 (en) 2008-12-23 2015-01-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
HUE026235T2 (en) 2010-03-31 2016-06-28 Gilead Pharmasset Llc Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -IL) - 4-Fluoro-3-hydroxy-4-methyltetrahydrofuran-2-IL) methoxy) (phenoxy) phosphoryl) amino) propanoate
US20140086975A1 (en) 2010-10-15 2014-03-27 Rutgers, The State University Of New Jersey Hydrogel formulation for dermal and ocular delivery
BR122021014365B1 (pt) 2012-10-11 2022-07-05 Daiichi Sankyo Company, Limited Conjugado de anticorpo-fármaco, fármacos e composição farmacêutica compreendendo os mesmos, e uso
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
PL3088419T3 (pl) 2013-12-25 2019-03-29 Daiichi Sankyo Company, Limited Koniugat lek-przeciwciało anty-trop2
CA2928794C (en) 2014-01-31 2019-08-13 Daiichi Sankyo Company, Limited Anti-her2 antibody-drug conjugate
KR102186027B1 (ko) 2014-04-10 2020-12-03 다이이치 산쿄 유럽 게엠베하 항her3 항체-약물 콘주게이트
EP3130608B1 (en) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
WO2017002776A1 (ja) 2015-06-29 2017-01-05 第一三共株式会社 抗体－薬物コンジュゲートの選択的製造方法
EP3552626A4 (en) 2016-12-12 2020-06-10 Daiichi Sankyo Company, Limited ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR
WO2018135501A1 (ja) 2017-01-17 2018-07-26 第一三共株式会社 抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体－薬物コンジュゲート
TW202330036A (zh) 2017-05-15 2023-08-01 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
US11318212B2 (en) 2017-08-31 2022-05-03 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
AU2018327171B2 (en) 2017-08-31 2023-03-09 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
US20210187118A1 (en) 2018-05-18 2021-06-24 Daiichi Sankyo Co., Ltd. Anti-muc1 antibody-drug conjugate
CA3114137A1 (en) 2018-09-26 2020-04-02 Jiangsu Hengrui Medicine Co., Ltd. Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof
AU2019351427A1 (en) 2018-09-30 2021-04-15 Changzhou Hansoh Pharmaceutical Co., Ltd. Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof
JP7210770B2 (ja) 2019-03-29 2023-01-23 メドイミューン・リミテッド 化合物及びその複合体
AU2020309570A1 (en) 2019-07-10 2022-02-03 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
JP2022541747A (ja) 2019-07-10 2022-09-27 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
KR20220113728A (ko) 2019-12-12 2022-08-16 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항 클라우딘 항체 약물 접합체 및 그 의약 용도
MX2022008474A (es) 2020-01-22 2022-08-02 Jiangsu Hengrui Medicine Co Conjugado de anticuerpo anti-trop-2-analogo de exatecan y uso medico del mismo.
CN115103691A (zh) 2020-03-25 2022-09-23 江苏恒瑞医药股份有限公司 一种含抗体药物偶联物的药物组合物及其用途
WO2021190583A1 (zh) 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 抗psma抗体-依喜替康类似物偶联物及其医药用途
CA3175048A1 (en) 2020-03-25 2021-09-30 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Preparation method for antibody medicament conjugate
WO2023030364A1 (zh) * 2021-09-01 2023-03-09 上海弼领生物技术有限公司 一种喜树碱类化合物、其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6087746A (ja) * 1983-10-17 1985-05-17 Hakubakumai Kk 即席麺ないしは焼そば用蒸し麺の製造方法
US4939255A (en) * 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JP3008226B2 (ja) * 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
US5658920A (en) * 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
IS4152A (is) * 1993-04-29 1994-10-30 Glaxo Inc. Vatnsuppleysanlegar Camptothecin afleiður og aðferð til framleiðslu þeirra
GB9319944D0 (en) * 1993-09-28 1993-11-17 Erba Carlo Spa Process for the preparation of 9-amino camptothecin

Also Published As

Publication number Publication date
DE69603117D1 (de) 1999-08-12
EA000036B1 (ru) 1998-02-26
ES2136338T3 (es) 1999-11-16
DK0737686T3 (da) 1999-11-22
EA199600018A2 (ru) 1996-10-01
ATE181919T1 (de) 1999-07-15
GR3031400T3 (en) 2000-01-31
EA199600018A3 (ru) 1997-03-31
US6504029B1 (en) 2003-01-07
CA2173671A1 (en) 1996-10-11
US20010034446A1 (en) 2001-10-25
TW382630B (en) 2000-02-21
AU5056696A (en) 1996-10-24
EP0737686A1 (en) 1996-10-16
KR100400941B1 (ko) 2003-12-24
DE69603117T2 (de) 1999-10-28
US6552197B2 (en) 2003-04-22
CN1050131C (zh) 2000-03-08
NO961405D0 (no) 1996-04-09
AU692078B2 (en) 1998-05-28
EP0737686B1 (en) 1999-07-07
NO961405L (no) 1996-10-11
CN1133290A (zh) 1996-10-16
NO314085B1 (no) 2003-01-27

Similar Documents

Publication Publication Date Title
KR960037682A (ko) 축합 6환 화합물 및 그의 제조방법
KR840005448A (ko) 티에노〔3, 2-c〕 피리딘 유도체의 제조방법
DE69030206T2 (de) Pyrazolopyridinverbindungen und Verfahren zu ihrer Herstellung
BR9401482A (pt) 1H-Indol-3-acetamida, formulação farmacêutica, utilização de um composto e processo para a preparação de 1h-indol-3-acetamida
MA20322A1 (fr) Nouveaux derives de n-(4-piperidinyl)-bicyclo condenses 2-imidozolamine et procede pour leur preparation
EP1462447A3 (en) Method for the preparation of pure citalopram
ATE46696T1 (de) 1- und 1,1-disubstituierte, 6-substituierte, 2carbamimidoyl-1-carbadethiapen-2-em-3carbons|uren, verfahren zur herstellung und diese enthaltende antibiotische zusammensetzung.
KR910009712A (ko) 세펨 화합물 및 이의 제조방법
KR910000630A (ko) 할로겐 치환 디페닐 설파이드, 이의 제조방법 및 우울증 치료제로서의 용도
ATE48001T1 (de) Cephemverbindungen, verfahren zu ihrer herstellung und ihre pharmazeutischen praeparate.
KR900018048A (ko) 환 치환된 2-아미노-1,2,3,4-테트라하이드로나프탈렌
KR910000607A (ko) 새로운 에스테르
EA199800155A1 (ru) Новое соединение
PT92952A (pt) Processo para a preparacao de acidos 3-fenil-5,6-di-hidrobenz { c }acridina-7- carboxilicos, de compostos relacionados e de composicoes farmaceuticas que os contem
ATE118217T1 (de) Natrium-n-acetylneuraminat-trihydrat und verfahren zu dessen herstellung.
KR900003179A (ko) 벤조디아제핀 화합물 및 약제로서의 이의 용도
DE69809888D1 (de) Verfahren zur Herstellung von alpha-Aminoketonen
KR920012011A (ko) 데아세틸콜히친 유도체
ATE70838T1 (de) Substituierte 3-aminosydnonimine, verfahren zu ihrer herstellung und ihre verwendung.
KR940021524A (ko) 1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법
KR900011771A (ko) 신규 벤조 [1,8] 나프티리딘 유도체, 그의 제조방법 및 그를 포함하는 조성물
DE60030118D1 (de) Zwischenprodukte zur synthese von benzimidazolverbindungen und ein verfahren zu ihrer herstellung
BR9902279A (pt) Método de purificação de precursores ésteres de carbazol do ácido 9-cloro-alfa-metil-carbazol-2-acético
PT92147A (pt) Processo para a preparacao de derivados de pirrolidina
KR910004632A (ko) 신규한 1-옥사-2-옥소-8-아자스피로[4,5]데칸 유도체와 그들을 포함하는 약제학적 조성물 및 그 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee